Literature DB >> 8504799

Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide.

G O Aspinall1, A G McDonald, T S Raju, H Pang, L A Kurjanczyk, J L Penner, A P Moran.   

Abstract

The complete structure for the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide (LPS) was assigned through studies on derivatives of the liberated oligosaccharide (OS 2) and the intact LPS. Structure determinations were performed using 1H-NMR spectroscopy, methylation studies supported by fast-atom-bombardment mass spectrometry and linkage analysis by gas chromatography/mass spectrometry, Smith degradation, and oxidation with chromium trioxide. It was concluded that complete oligosaccharide chains had the following structure: [formula: see text]

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8504799     DOI： 10.1111/j.1432-1033.1993.tb17850.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN： 0014-2956


  20 in total

Review 1.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

2.  Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome.

Authors:  A Neisser; H Bernheimer; T Berger; A P Moran; B Schwerer
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  Campylobacter jejuni-stimulated secretion of interleukin-8 by INT407 cells.

Authors:  T E Hickey; S Baqar; A L Bourgeois; C P Ewing; P Guerry
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Characterization of the Campylobacter jejuni heptosyltransferase II gene, waaF, provides genetic evidence that extracellular polysaccharide is lipid A core independent.

Authors:  Neil J Oldfield; Anthony P Moran; Lorna A Millar; Martina M Prendergast; Julian M Ketley
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

5.  Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro.

Authors:  Patricia Guerry; Christine M Szymanski; Martina M Prendergast; Thomas E Hickey; Cheryl P Ewing; Dawn L Pattarini; Anthony P Moran
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Lipooligosaccharide of Campylobacter jejuni: similarity with multiple types of mammalian glycans beyond gangliosides.

Authors:  R Scott Houliston; Evgeny Vinogradov; Monika Dzieciatkowska; Jianjun Li; Frank St Michael; Marie-France Karwaski; Denis Brochu; Harold C Jarrell; Craig T Parker; Nobuhiro Yuki; Robert E Mandrell; Michel Gilbert
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

7.  Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3.

Authors:  S Salloway; L A Mermel; M Seamans; G O Aspinall; J E Nam Shin; L A Kurjanczyk; J L Penner
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

8.  Enhanced, sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages.

Authors:  Astrid P Heikema; Roman I Koning; Sharon Duarte dos Santos Rico; Hans Rempel; Bart C Jacobs; Hubert P Endtz; Willem J B van Wamel; Janneke N Samsom
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

9.  Evidence for acquisition of the lipooligosaccharide biosynthesis locus in Campylobacter jejuni GB11, a strain isolated from a patient with Guillain-Barré syndrome, by horizontal exchange.

Authors:  Michel Gilbert; Peggy C R Godschalk; Marie-France Karwaski; C Wim Ang; Alex van Belkum; Jianjun Li; Warren W Wakarchuk; Hubert P Endtz
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1 a epitope.

Authors:  N Yuki; T Taki; M Takahashi; K Saito; T Tai; T Miyatake; S Handa
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.